US 12,303,618 B2
Oxygen-generating cryogels
Adnan Memic, Macomb, MI (US); Sidi A. Bencherif, Boston, MA (US); Michail Sitkovsky, Boston, MA (US); Thibault Colombani, Boston, MA (US); and Stephen Hatfield, Peabody, MA (US)
Assigned to Northeastern University, Boston, MA (US)
Appl. No. 17/266,351
Filed by Northeastern University, Boston, MA (US)
PCT Filed Aug. 8, 2019, PCT No. PCT/US2019/045740
§ 371(c)(1), (2) Date Feb. 5, 2021,
PCT Pub. No. WO2020/033713, PCT Pub. Date Feb. 13, 2020.
Claims priority of provisional application 62/716,132, filed on Aug. 8, 2018.
Prior Publication US 2021/0308334 A1, Oct. 7, 2021
Int. Cl. A61L 27/54 (2006.01); A61L 27/02 (2006.01); A61L 27/20 (2006.01); A61L 27/52 (2006.01)
CPC A61L 27/54 (2013.01) [A61L 27/025 (2013.01); A61L 27/20 (2013.01); A61L 27/52 (2013.01); A61L 2300/11 (2013.01); A61L 2300/254 (2013.01); A61L 2300/416 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A method of reducing hypoxia in a biological tissue, comprising administering to the biological tissue an oxygen-generating cryogel, wherein the administration is by injection, catheter, or surgery; and the cryogel comprises:
i) a lyoprotectant;
ii) a peroxide, an oxide or a percarbonate;
iii) a catalase, wherein the catalase is acrylate-PEG-catalase; and
iv) polymerized hyaluronic acid.